

DAFTAR PUSTAKA

- Adams, M. D., Nickel, G. C., Bajaksouzian, S., Lavender, H., Murthy, A. R., Jacobs, M. R., Bonomo, R.A. 2009. Resistance To Colistin In *Acinetobacter baumannii* Associated With Mutations In The PmrAB Two-Component System. *Antimicrobial Agents Chemotherapy*. 53: 3628–34
- Almasaudi, S.B. 2016. *Acinetobacter* spp as Nosocomial Pathogen: Epidemiology and Resistance Features. *Saudi Journal of Biological Sciences*. 25: 586-596
- Antunes, L. C., Imperi, F., Carattoli, A., Visca, P. 2011. Deciphering The Multifactorial Nature of *Acinetobacter baumannii* Pathogenicity. *PLoS ONE*. 16: 1-22
- Camarena, L., Bruno, V., Euskirchen, G., Poggio, S., Snyder, M. 2010. Molecular Mechanisms of Ethanol-Induced Pathogenesis Revealed by RNA Sequencing. *PLoS Pathology*. 6: 1-12
- Chang, Y., Luan, G., Xu, Y., Wang, Y., Shen, M., Zhang, C., Zheng, W., Huang, J., Yang, J., Jia, X., Ling, B. 2015. Characterization of Carbapenem Resistant *Acinetobacter baumannii* Isolates In A Chinese Teaching Hospital. *Frontiers in Microbiology*. 6: 910
- Chin, C. Y., Gregg, K. A., Napier, B. A., Ernst, R. K., Weiss, D. S. 2015. A PmrB-regulated Deacetylase Required for Lipid A Modification and Polymyxin Resistance in *Acinetobacter baumannii*. *Antimicrobial Agents Chemotherapy*. 59: 7911–791
- Cisneros, J. M., Rodriguez-Bano. 2002. Nosocomial bacteremia due to *Acinetobacter baumannii*: Epidemiology clinical features and treatment. *Clinical Microbiology and Infection*. 8: 687-92
- Cisneros, J.M., Rodriguez-Bano, J. 2002. Nosocomial Bacteremia due to *Acinetobacter baumannii*: Epidemiology, Clinical Features and Treatment. *European Society of Clinical Microbiology and Infectious Disease*. 8: 687-693
- Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Susceptibility Testing*, 29th Edition CLSI Supplement M100, Wayne Pennsylvania, Clinical and Laboratory Standards Institute
- del Mar Tomas, M., Beceiro, A., Perez, A., Velasco, D., Moure, R., Villanueva, R., Beltran, J.M., Bou, G. 2005. Cloning and Functional Analysis of The Gene Encoding The 33-to 36-kilodalton Outer Membrane Protein

- Associated With Carbapenem Resistance in *Acinetobacter baumannii*. *Antimicrobiology Agents Chemotherapy*. 49: 5172–5175
- Erridge, C., Moncayo-Nieto, O. L., Morgan, R., Young, M., Poxton, I. R. 2007. *Acinetobacter baumannii* Lipopolysaccharides are Potent Stimulators of Human Monocyte Activation via Toll-like Receptor 4 Signalling. *Journal Medical Microbiology*. 56: 165–171
- Evans, B. A., Hamouda, A., Amyes, S. G. B. 2013. The Rise of Carbapenem-Resistant *Acinetobacter baumannii*. *Current Pharmaceutical Design*. 19: 223-28
- Falagas, M. E., Vardakas, K. Z., Kapaskelis, A., Triarides, N. A., Roussos, N. S. 2015. Tetracyclines for Multidrug-Resistant *Acinetobacter baumannii* Infection. *International Journal of Antimicrobial Agents*
- Falagas, M. E., Vardakas, K. Z., Roussos, N. S. 2015. Trimethoprim-Sulfamathoxazole for *Acinetobacter* spp: A Review of Current Microbiological and Clinical Evidence. *International Journal of Antimicrobial Agents*. 46: 231-241
- Finch, R. D., Greenwood, D., Norby, S. R., Withley, R. J. 2010. *Antibiotic and Chemotherapy: Anti-Infective Agent and Their Use in Therapy 9th Edition*. Elsevier. New York.
- Fournier, P. E., Richet, H. 2006. The Epidemiology and Control of *Acinetobacter baumannii* in Health Care Facilities. *Clinical Infectious Disease*. 42: 692–699
- Geisinger, E., Isberg, R. R. 2015. Antibiotic Modulation of Capsular Exopolysaccharide and Virulence in *Acinetobacter baumannii*. *PLoS Pathogenesis*. 11: 1-22
- Hasani, A., Sheikhalizadeh, V., Ahangarzadeh Rezaee, M., Rahmati-Yamchi, M., Hasani, A., Ghotaslou, R., Goli, H. R. 2016. Frequency of Aminoglycosidemodifying Enzymes and ArmA among Different Sequence Groups of *Acinetobacter baumannii* In Iran. *Microbial Drug Resistance*. 22: 347–353
- Hood, M. I., Mortensen, B. L., Moore, J. L., Zhang, Y., Kehl-Fie, T. E., Sugitani, N., Chazin, W. J., Caprioli, R. M., Skaar, E. P. 2012. Identification of An *Acinetobacter baumannii* Zinc Acquisition System That Facilitates Resistance To Calprotectin-Mediated Zinc Sequestration. *PLoS Pathogens*.
- Hu, D., Liu, B., Dijkshoorn, L., Wang, L., Reeves, P. R. 2013. Diversity in The Major Polysaccharide Antigen of *Acinetobacter baumannii* Assessed by DNA Sequencing, and Development of a Molecular Serotyping Scheme. *PLoS ONE*. 8

- Hu, W. S., Yao, S. M., Fung, C. P., Hsieh, Y. P., Liu, C. P., Lin, J. F. 2007. An OXA-66/OXA-51-Like Carbapenemase and Possibly an Efflux Pump are Associated with Resistance to Imipenem in *Acinetobacter baumannii*. *Antimicrobiology Agents Chemotherapy*. 51: 3844–52
- Jeon, J. H., Lee, J. H., Lee, J. J., Park, K. S., Karim, A. M., Lee, C. R., Jeong, B. C., Lee, S. H. 2015. Structural Basis for Carbapenem-Hydrolyzing Mechanisms of Carbapenemases Conferring Antibiotic Resistance. *International Journal Molecul Science*. 16: 9654–92
- Johnson, T. L., Waack, U., Smith, S., Mobley, H., Sandkvist, M. 2015. *Acinetobacter baumannii* is Dependent on the Type II Secretion System and Its Substrate Lipa for Lipid Utilization and In Vivo Fitness. *Journal Bacteriology*. 198: 711–19
- Jun, S. H., Lee, J. H., Kim, B. R., Kim, S. I., Park, T. I., Lee, J. C., Lee, Y. C.. 2013. *Acinetobacter baumannii* Outer Membrane Vesicles Elicit A Potent Innate Immune Response Via Membrane Proteins. *PLoS ONE*. 8: 1-7
- Korotkov, K. V., Sandkvist, M., Hol, W. G. 2012. The Type II Secretion System: Biogenesis, Molecular Architecture and Mechanism. *Nature Review Microbiology*. 10: 336–51
- Kwon, S. O., Gho, Y. S., Lee, J. C., Kim, S. I. 2009. Proteome Analysis of Outer Membrane Vesicles from A Clinical *Acinetobacter baumannii* Isolate. *FEMS Microbiology Letters*. 297: 150–56
- Leber, A. L. 2016. *Clinical microbiology procedures handbook 4th Edition*. ASM Press. Washington DC
- Lee, C. R., Lee, J. H., Jeong, B. C., Lee, S. H. 2013b. Lipid a biosynthesis of multidrug-resistant pathogens a novel drug target. *Current Pharmaceutical Design*. 19: 6534–50
- Lee, C.R., Lee, J. H., Park, M., Park, K. S., Bae, I. K., Kim, Y. B., Cha, C., Jeong, B. C., Lee, S. H. 2017. Biologi of *Acinetobacter baumannii*: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment options. *Frontiers in Celluler and Infection Microbiology*. 1-22
- Lee, H.Y., Chen CL., Wu SR., Huang CW., Chiu CH. 2014. Risk Factors and Outcome Analysis of *Acinetobacter Baumannii* Complex Bacteremia in Critical Patients. *Critical Care Medecine*. 42(5): 1081-88
- Lemos, EV., de la Hoz FP., Einarson TR., McGhan WF., Quevedo E., Castaneda C, Kawai, K. 2014. Carbapenem Resistance and Mortality in Patients with *Acinetobacter Baumannii* Infection: Systematic Review and Meta-Analysis. *Clinical Microbiology Infection*, vol 20 (5), hal 416-423

- Lin, M. F., Lan, C. Y. 2014. Antimicrobial resistance in *Acinetobacter baumannii*: from bench to bedside. *World Journal of Clinical Cases*. 2: 787–814
- Liu, J., Wang, F., Ho, M., Lee, C., Liu, J., Wang, J., Sheng, W., Hseuh, P., Chang, S. 2016. In Vitro Activity of Aminoglycosides against Clinical Isolates of *Acinetobacter baumannii complex* and Other Nonfermentative Gram Negative Bacilli Causing Healthcare-Associated Bloodstream Infection in Taiwan. *Journal of Microbiology, Immunology and Infection*. 49: 918-23
- Magnet, S., Courvalin, P., Lambert, T. 2001. Resistance-Nodulationcell Division-Type Efflux Pump Involved In Aminoglycoside Resistance in *Acinetobacter Baumannii* Strain BM4454. *Antimicrobial Agents Chemotherapy*. 45: 3375–80
- Manchanda, V., Sanchaita, S., Singh, N.P. 2010. Multi Drug Resistant *Acinetobacter baumannii*. *Journal of Global Infectious Disease*. 2: 3
- McConnell, M. J., Actis, L., Pachon, J. 2013. *Acinetobacter baumannii*: Human Infections, Factors Contributing to Pathogenesis and Animal Models. *FEMS Microbiology Review*. 37: 130–155.
- McQueary, C. N., Kirkup, B. C., Si, Y., Barlow, M., Actis, L. A., Craft, D. W., Zurawski, D. V. 2012. Extracellular Stress and Lipopolysaccharide Modulate *Acinetobacter baumannii* Surface-Associated Motility. *Journal Microbiology*. 50: 434–443
- Megeed, A. A., Hayssam, M. A., Salem, M. Z., El-Shikh, M. S., Talea, I. A., Alogaibi, Y. A. 2016. Investigation of The Virulence Factors and Molecular Characterization of The Clonal Relations of Multidrug-Resistant *Acinetobacter baumannii* isolates. *Journal AOAC International*
- Moffatt, J. H., Harper, M., Harrison, P., Hale, J. D., Vinogradov, E., Seemann, T., Rebekah, H., Crane, B., St Michael, F., Cox, A. D., Adler, B., Nation, R. L., Li, Jian., Boyce, J. D. 2010. Colistin Resistance in *Acinetobacter baumannii* is Mediate by Complete Loss of Lipopolysaccharide Production. *Antimicrobial Agents Chemotherapy*. 54: 4971–77
- Moffatt, J. H., Harper, M., Harrison, P., Hale, J. D., Vinogradov, E., Seemann, T., Henry, R., Crane, B., St Michael, F., Cox, A. D., Adler, B., Nation, R. L., Li, J., Boyce, J. D. 2010. Colistin Resistance in *Acinetobacter baumannii* is Mediate by Complete Loss of Lipopolysaccharide Production. *Antimicrobial Agents Chemotherapy*. 54: 4971–77
- Monteiro-Neto, V., Lima-Neto, L. G., Abreu, A. G., & Monteiro, C. R. A. V. 2017. Microbiology of Ventilator-Associated Pneumonia. In: Chronos, Z. (Ed.). Contemporary Topics of Pneumonia.

- Montero, J. G., Amaya-Villar, R., Million, C. F., Martin, A. D., Sanchez, M. L., Pizzaraya, A. G. 2015. Optimum treatment strategies for carbapenem-resistant *Acinetobacter baumannii* bacteremia. *Expert Review of Anti Infective Therapy*. 1-9
- Moon, D. C., Choi, C. H., Lee, J. H., Choi, C. W., Kim, H. Y., Park, J. S., Kim, S. I., Lee, J. C. 2012. *Acinetobacter baumannii* Outer Membrane Protein A Modulates the Biogenesis of Outer Membrane Vesicles. *Journal Microbiology*. 50: 155–160
- Mugnier, P. D., Poirel, L., Naas, T., Nordmann, P. 2010. Worldwide Dissemination of The *bla*OXA-23 Carbapenemase Gene of *Acinetobacter baumannii*. *Emerging Infectious Disease Journal*. 16: 135–40
- Nemec, A., Dolzani, L., Brisse, S., van den Broek, P., Dijkshoorn, L. 2004. Diversity of Aminoglycoside-Resistance Genes and Their Association with Class 1 Integrons among Strains of Pan-European *Acinetobacter baumannii* Clones. *Journal of Medical Microbiology*. 53: 1233–40
- Peleg, A. Y., Adams, J., Paterson, D. L. 2007. Tigecycline Efflux as A Mechanism For Nonsusceptibility In *Acinetobacter baumannii*. *Antimicrobial Agents Chemotherapy*. 51: 2065–69
- Peleg, A.Y., Seifert, H., Paterson, D.L. 2008. *Acinetobacter baumannii*: Emergence of A Successful Pathogen. *Clinical Microbiology Review*. 21: 538-582
- Poirel, L., Jayol, A., Nordmann, P. 2017. Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes. *Clinical Microbiology Reviews*. 30: 558-96
- Quale, J., Bratu, S., Landman, D., Heddurshetti, R. 2003. Molecular Epidemiology and Mechanisms of Carbapenem Resistance in *Acinetobacter baumannii* Endemic in New York City. *Clinical Infectious Disease*. 37: 214–20.
- Ribera, A., Ruiz, J., Vila, J. 2003. Presence of The Tet M Determinant In A Clinical Isolate of *Acinetobacter baumannii*. *Antimicrobial Agents Chemotherapy*. 47: 2310–12
- Roca, I., Marti, S., Espinal, P., Martinez, P., Gibert, I., Vila, J. 2009. CraA, A Major Facilitator Superfamily Efflux Pump Associated With Chloramphenicol Resistance in *Acinetobacter baumannii*. *Antimicrobial Agents Chemotherapy*. 53: 4013–14
- Rumbo, C., Fernandez-Moreira, E., Merino, M., Poza, M., Mendez, J. A., Soares, N. C., Mosquera, A., Chaves, F., Bou, G. 2011. Horizontal Transfer Of The OXA-24 Carbapenemase Gene Via Outer Membrane Vesicles: A New Mechanism of Dissemination of Carbapenem Resistance Genes in

- Acinetobacter baumannii*. *Antimicrobial Agents Chemotherapy*. 55: 3084–90
- Russo, T. A., MacDonald, U., Beanan, J. M., Olson, R., MacDonald, I. J., Sauberan, S. L., Luke, N. R., Scultz, L. W., Umland, T. C.. 2009. Penicillin-Binding Protein 7/8 Contributes to The Survival of *Acinetobacter baumannii* *In Vitro* and *In Vivo*. *Journal Infectious Disease*. 199: 513–21
- Ruzin, A., Keeney, D., Bradford, P. A. 2007. AdeABC Multidrug Efflux Pump Is Associated with Decreased Susceptibility to Tigecycline In *Acinetobacter calcoaceticus*-*Acinetobacter baumannii* complex. *Journal of Antimicrobial Chemotherapy*. 59: 1001–04
- Saha, R., Saha, N., Donofrio, R. S., Bestervelt, L. L. 2013. Microbial Siderophores: A Mini Review. *Journal Basic Microbiology*. 53: 303–17
- Sechi, L. A., Karadenizli, A., Deriu, A., Zanetti, S., Kolayli, F., Balikci, E., Vahaboqlu, H. 2004. PER-1 Type B-Lactamase Production in *Acinetobacter baumannii* is Related To Cell Adhesion. *Medical Science Monitor*. 10
- Smani, Y., Fabrega, A., Roca, I., Sanchez-Encinales, V., Vila, J., Pachon, J. 2014. Role of OmpA in The Multidrug Resistance Phenotype of *Acinetobacter baumannii*. *Antimicrobiology Agents Chemotherapy*. 58: 1806–08
- Srinivasan, V. B., Venkataramaiah, M., Mondal, A., Rajamohan, G. 2015. Functional Characterization of AbeD, An RND-type Membrane Transporter In Antimicrobial Resistance In *Acinetobacter baumannii*. *PLoS ONE*. 10
- Su, X. Z., Chen, J., Mizushima, T., Kuroda, T., Tsuchiya, T. 2005. AbeM, An H⁺-coupled *Acinetobacter baumannii* Multidrug Efflux Pump Belonging To The MATE Family of Transporters. *Antimicrobial Agents Chemotherapy*. 49: 4362–64
- Sugawara, E., Nikaido, H. 2012. OmpA is The Principal Nonspecific Slow Porin of *Acinetobacter baumannii*. *Journal Bacteriology*. 194: 4089–96
- Taitt, C. R., Leski, T. A., Stockelman, M. G., Craft, D. W., Zurawski, D. V., Kirkup, B. C., Vora. G. J. 2014. Antimicrobial Resistance Determinants In *Acinetobacter baumannii* Isolates Taken From Military Treatment Facilities. *Antimicrobial Agents Chemotherapy*. 58: 767–81
- Tille, P. M. 2014. *Bailey and Scott Diagnostic Microbiology Edithion 13th*. Missiori: Elsevier

- Viehman, J. A., M. Nguyen, H., Doi, Y. 2014. Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant *Acinetobacter baumannii* Infections. *Springer International Publishing*.
- Vincent, J. L., Rello, J., Marshall, J., Silva, E., Anzueto, A., Martin, C. D., Moreno, R., Lipman, J., Gomersall, C. M., Sakr, Y., Reinhart, K. 2009. International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. *JAMA*. 302: 2323–29
- Weber, B. S., Ly, P. M., Irwin, J. N., Pukatzki, S., Feldman, M. F. 2015. A Multidrug Resistance Plasmid Contains the Molecular Switch for Type VI Secretion in *Acinetobacter baumannii*. *Proceedings of the National Academy Science U.S.A.* 112: 9442–47
- World Health Organization. 2017. Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. <https://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/.com>. [27 Februari 2017]
- Yang, Y. S., Lee, Y., Tseng, K. C., Huang, W. C., Chuang, M. F., Kuo, S. C., Lauderdale, T. L., Chen, T. L. 2016. *In vivo* and *in vitro* efficacy of minocycline-based combination therapy for minocycline-resistant *Acinetobacter baumannii*. *Antimicrobiology Agents Chemotherapy*. 60: 4047–54